Twist Bioscience Stock Dips on Earnings Miss

Twist Bioscience (NASDAQ:TWST) saw its stock price decrease by 4.2% in pre-market trading on August 5, 2026. This followed the company's fiscal third-quarter financial report, which presented a mixed performance. Revenue for the quarter reached $118.4 million, exceeding market predictions of $114.54 million, indicating strong demand for its DNA synthesis products.

However, the company's bottom-line results continued to be a point of concern. Twist Bioscience reported a quarterly loss of $0.56 per share, which was wider than the anticipated $0.48 loss. This marks a continuing trend from earlier in fiscal 2026, as both the first and second quarters also saw weaker-than-expected earnings.

Despite these profitability challenges, Twist Bioscience is demonstrating robust commercial momentum. The consistent revenue growth supports its long-term outlook, though investors are focused on the company's ability to translate this sales increase into improved profitability. Market participants await further commentary from management's upcoming earnings call for insights into achieving stronger margins and sustainable profitability.